Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports.
Galmed Pharmaceuticals Stock Up 0.2%
Shares of GLMD opened at $0.57 on Thursday. The company has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.66. Galmed Pharmaceuticals has a twelve month low of $0.41 and a twelve month high of $2.34. The company has a market cap of $3.12 million, a price-to-earnings ratio of -0.46 and a beta of 0.75.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.
Institutional Trading of Galmed Pharmaceuticals
An institutional investor recently bought a new stake in Galmed Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 3.05% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 76.14% of the company’s stock.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.
In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
